Component-Level Trial Findings CJC-1295 (without DAC, modified GRF 1-29) Phase 1 and Phase 2 work described: Dose-dependent GH elevation (2-10x baseline at studied doses, PMID 16352683) IGF-1 elevation of 1.5-3x baseline at 1-2 weeks Mild facial flushing post-injection in some participants No serious adverse events at studied doses CJC-1295 with DAC The DAC-modified version covalently binds to albumin, extending half-life to 5-8 days (PMID 16352683)
Everything else the review included, 35 of 36 studies, was done in animals, much of it by a single Croatian research group going back to the 1990s1
From mild breakouts to severe cystic acne, it can lead to frustration, discomfort, and even long-term skin damage
Feels like a real program, not a quick checkout
Description Overview of BPC-157 / TB-500 Peptide Blend BPC-157/TB-500 Blend -Research Grade This expertly manufactured research grade peptide blend is a result of two widely studied peptides BPC-157andTB-500- combined to explore any synergistic or other beneficial effects that may arise from their co-application